EVALUATING THE ROLE OF REAL-WORLD EVIDENCE FOR ONCOLOGY PRODUCT REGISTRATION IN THE UNITED STATES: A SYSTEMATIC REVIEW OF APPROVALS BY THE FOOD AND DRUG ADMINISTRATION FROM 2015-2019

被引：0
|
作者：
Duh, M. S. [1 ]
Bhak, R. [1 ]
Arondekar, B. [2 ]
DerSarkissian, M. [3 ]
Huynh, L. [1 ]
Wojciehowski, J. [1 ]
Wu, M. [1 ]
Wornson, B. [2 ]
Schrag, D. [4 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Pfizer Inc, Collegeville, PA USA
[3] Anal Grp Inc, Los Angeles, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN209
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 40 条
  • [1] Role of real-world evidence for oncology product registration in the United States: A review of approvals by the US Food and Drug Administration from 2015 to 2019.
    Arondekar, Bhakti
    Bhak, Rachel
    DerSarkissian, Maral
    Huynh, Lynn
    Wang, Kelsey
    Davis, Eric
    Wornson, Bryon
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020
    Arondekar, Bhakti
    Duh, Mei Sheng
    Bhak, Rachel H.
    DerSarkissian, Maral
    Huynh, Lynn
    Wang, Kelsey
    Wojciehowski, John
    Wu, Melody
    Wornson, Bryon
    Niyazov, Alexander
    Demetri, George D.
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 27 - 35
  • [3] Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022
    Zhang, Xiaofang
    Peck, Carl C.
    Wang, Yaning
    Szucs, Thomas D.
    Sun, Wan
    Bai, Xue
    Chen, Siyu
    Wang, Fengzhi
    Wu, Yangfeng
    BMC MEDICINE, 2024, 22 (01):
  • [4] Real-world evidence for US Food and Drug Administration-approved oncology products, 2015 to 2020.
    Arondekar, Bhakti
    Duh, Mei Sheng
    Bhak, Rachel
    DerSarkissian, Maral
    Huynh, Lynn
    Wang, Kelsey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [5] An update from the US Food and Drug Administration on real-world data and real-world evidence
    Dal Pan, Gerald J.
    ANNALS OF ONCOLOGY, 2022, 33 : S407 - S407
  • [6] Epidemiology of drug arrests in the United States: Evidence from the national survey on drug use and health, 2015-2019
    Rouhani, Saba
    Luo, Lingzi
    Byregowda, Himani
    Weaver, Nicholas
    Park, Ju Nyeong
    PREVENTIVE MEDICINE, 2024, 185
  • [7] Trends in post-approval pregnancy safety studies required by the United States food and drug administration, 2015-2019
    Simeone, Jason C.
    Nordstrom, Beth L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 549 - 549
  • [8] Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
    Lau, Catherine
    Dranitsaris, George
    CURRENT ONCOLOGY, 2022, 29 (11) : 8031 - 8042
  • [9] Real-World Evidence (RWE) Studies Supported Hematologic Oncology United States Food and Drug Administration (US FDA) Approval: What Do They Look like?
    Yue, Binglin
    Greenbaum, Adam
    Sun, Shaohui
    Zhu, Enda
    Weng, Shicheng
    Du, Chenmu
    Zhang, Xiaojuan
    Liao, Shanmei
    BLOOD, 2022, 140 : 13208 - 13209
  • [10] A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases
    Vaghela, Shailja
    Tanni, Kaniz Afroz
    Banerjee, Geetanjoli
    Sikirica, Vanja
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
1234